Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

TG103

A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Completed · Enrollment 314

NCT06226090

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
TG103 7.5 mgn/rn/rn/rn/r
Placebo 7.5 mgn/rn/rn/rn/r
TG103 15 mgn/rn/rn/rn/r
Placebo 15 mgn/rn/rn/rn/r
TG103 22.5 mgn/rn/rn/rn/r
Placebo 22.5 mgn/rn/rn/rn/r

Not shown

  • TG103 7.5 mg: endpoint not reported
  • Placebo 7.5 mg: endpoint not reported
  • TG103 15 mg: endpoint not reported
  • Placebo 15 mg: endpoint not reported
  • TG103 22.5 mg: endpoint not reported
  • Placebo 22.5 mg: endpoint not reported